Dosing and administration

VYXEOS (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) liposome dose and schedule1
Administered intravenously as a 90-minute infusion
Dose Dosing schedule
First induction daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 liposome Days 1, 3, and 5
Second induction
(in patients not achieving a response, start 2 to 5 weeks after first induction if no unacceptable toxicity)
daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 liposome Days 1 and 3
Consolidation
(5 to 8 weeks after the start of last induction)
daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 liposome Days 1 and 3
  • VYXEOS is supplied in a single-dose vial containing 44 mg of daunorubicin and 100 mg of cytarabine1
  • Calculate the number of vials of VYXEOS needed based on the daunorubicin dose

Dosing considerations

  • Prior to initiating each cycle, calculate the prior cumulative anthracycline exposure for the patient
  • Assess cardiac function, complete blood counts, and liver and renal function before each consolidation cycle
  • Do not start consolidation until the absolute neutrophil count recovers to greater than 0.5 Gi/L and the platelet count recovers to greater than 50 Gi/L in the absence of unacceptable toxicity
  • Administer the second consolidation cycle 5 to 8 weeks after the start of the first consolidation cycle in patients who do not show disease progression or unacceptable toxicity